Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Zevra Therapeutics (ZVRA) over the last 7 years, with Q3 2025 value amounting to $145.1 million.

  • Zevra Therapeutics' Short-term Investments rose 31053.29% to $145.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.1 million, marking a year-over-year increase of 31053.29%. This contributed to the annual value of $35.7 million for FY2024, which is 4464.92% up from last year.
  • Zevra Therapeutics' Short-term Investments amounted to $145.1 million in Q3 2025, which was up 31053.29% from $154.9 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Short-term Investments high stood at $154.9 million for Q2 2025, and its period low was $1.3 million during Q1 2022.
  • Over the past 4 years, Zevra Therapeutics' median Short-term Investments value was $24.7 million (recorded in 2023), while the average stood at $37.6 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Short-term Investments surged by 247122.57% in 2023, and later tumbled by 7131.65% in 2024.
  • Zevra Therapeutics' Short-term Investments (Quarter) stood at $16.9 million in 2022, then surged by 46.08% to $24.7 million in 2023, then skyrocketed by 44.65% to $35.7 million in 2024, then soared by 306.23% to $145.1 million in 2025.
  • Its Short-term Investments stands at $145.1 million for Q3 2025, versus $154.9 million for Q2 2025 and $25.3 million for Q1 2025.